The study investigator calculates observed sensitivity using the number of observed cases of disease in the trial as the denominator.
At this point retraining of staff and the introduction of quality improvement measures occurred and observed sensitivity improved slightly to 95.1% over the final two months of observation.
Finally, we observed sensitivity of the results to the total number of genes d.
We also observed sensitivity to predictable dynamics in bilateral premotor areas.
We observed sensitivity of Wv method to be 0.73 and specificity to be 0.96.
To explore the heterogeneity observed, sensitivity analyses were performed by sequential exclusion of each study.
Therefore observed sensitivity for Ebola screening has been 0%, which is lower than our model-predicted value of around 50%.
At these cutoffs, we observed sensitivity 52%, specificity 76%, PPV 63% and NPV 68% for no/minimal fibrosis and 60%, 63%, 68% and 55% for advanced fibrosis, respectively.
At the maximum observed sensitivity + specificity, sensitivity was 49.5%, specificity was 63.9% and positive and negative predictive values were 9.3 and 94.4%, respectively.
Observed sensitivity was 93.5% over five months.
We use a similar technique to calculate the observed sensitivity and observed specificity.
